$3.36 million cash and $3.42 million loss shape Patrys outlook

• First participants dosed in RLS-2202 Phase 1A trial after year-end
• $3.42 million FY2026 net loss and $2.17 million operating cash outflow
• Material going concern uncertainty linked to future funding requirements
• $6.636 million RLS-2202 intangible recognised after Reliis acquisition
• Yale agreement gives Patrys 50% of future deoxymab commercialisation revenue

RLS-2202 reaches human testing

Patrys Limited (ASX:PAB) has reached a clinical milestone with RLS-2202, but the annual report makes clear that the next stage will depend on more than trial execution. The company disclosed that first participants were dosed in Cohort 1 of the Phase 1A study on 23 September, after receiving Human Research Ethics Committee approval and TGA acknowledgement for the trial.

The study is designed to assess safety, tolerability and bridging pharmacokinetics in healthy volunteers. Patrys had already completed an engineering batch at BioCina and appointed CMAX as the clinical site, with Alithia Life Sciences overseeing the broader clinical and regulatory program. The filing does not report any clinical results yet, so the trial remains an early safety and pharmacokinetic test rather than evidence of efficacy in patients with delirium.

Cash improved, but funding remains unresolved

Patrys finished the year with $3.36 million in cash, up from $742,441 a year earlier, after completing a $1.77 million entitlement offer and a $3.15 million placement before costs. That stronger balance did not remove the central financial constraint: the company recorded a $3.42 million net loss and used $2.17 million in operating cash during FY2026.

The directors state that cash-flow forecasts indicate further capital will be required within the next 12 months to continue planned operations. The accounts therefore contain a “material uncertainty” that may cast significant doubt on the group’s ability to continue as a going concern. No definitive funding agreement had been entered into at the report date, leaving equity issuance, spending reductions or other financing arrangements as unresolved parts of the company’s near-term plan.

That pressure sits alongside $2.64 million of contracted research and development commitments for services not yet provided. Patrys also did not recognise an R&D tax incentive for FY2026 because management said there was insufficient evidence at year-end to support recognition, removing a source of income that contributed $807,271 in the prior year.

Reliis acquisition reshapes the asset base

The acquisition of Reliis, completed in January, added RLS-2202 to Patrys’ portfolio and produced a $6.636 million in-process research and development intangible asset, alongside $32,000 of goodwill. The acquisition consideration was valued at $6.75 million and included shares, performance rights, convertible notes and vendor facilitation shares.

The accounting valuation depends on assumptions about future revenue, technical and regulatory success, development timing, commercialisation costs and discount rates. Patrys reported no impairment against the asset at 30 June, but the report acknowledges that changes in those assumptions could materially affect its value in future periods.

Yale arrangement shifts deoxymab funding burden

After year-end, Patrys entered into a binding agreement with Yale University covering the deoxymab intellectual property portfolio. Yale is to take responsibility for the majority of future research and development costs after the IP is assigned, while Patrys will be entitled to 50% of future commercialisation revenue directly attributable to the portfolio, including licensing income, royalties, milestones and certain non-cash consideration.

The arrangement is intended to transfer the IP into a new Yale-linked start-up in which Patrys would become a direct shareholder. Patrys says it will continue supporting pre-clinical work on PAT-DX1 and PAT-DX3, including the Monash University ANCA-associated vasculitis program, while materially reducing its future capital commitments to deoxymab. That offers a different funding model for the platform, but it does not resolve the immediate financing requirement attached to the group as a whole.

Bottom Line?

The immediate test is whether Patrys can fund the RLS-2202 program through early clinical development without allowing the going concern warning to become the dominant story.

Questions in the middle?

• What funding structure will Patrys pursue before its cash position becomes restrictive?
• Will Phase 1A data support progression beyond safety and pharmacokinetic testing?
• How quickly can the Yale arrangement convert deoxymab research into commercial or financing value?